Premium
Expression of Decay Accelerating Factor in Endometrial Adenocarcinoma is Inversely Related to the Stage of Tumor
Author(s) -
Nowicki S.,
Nowicki B.,
Pham T.,
Hasan R.,
Nagamani M.
Publication year - 2001
Publication title -
american journal of reproductive immunology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.071
H-Index - 97
eISSN - 1600-0897
pISSN - 1046-7408
DOI - 10.1111/j.8755-8920.2001.460205.x
Subject(s) - decay accelerating factor , endometrial cancer , adenocarcinoma , endometrium , stage (stratigraphy) , cancer research , complement system , medicine , cell culture , biology , endocrinology , cancer , immunology , antibody , genetics , paleontology
PROBLEM: Decay accelerating factor (DAF) is implicated in protection of cell membrane from toxicity of complement. In this study, we investigated a hypothesis that DAF is up‐regulated in the endometrial adenocarcinoma, which could increase potential of malignant cells to escape destruction by complement.
METHODS: DAF density was evaluated in endometrial biopsies of patients with adenocarcinoma at various stages and compared with ten endometrial biopsies from non‐malignant patients at the proliferative phase.
RESULTS: DAF expression in normal proliferative endometrium varied between 1 and 30%. While DAF density in patients with stage I cancer was in the range 56–98% (mean 78%), stage III values varied from 28 to 16% (mean 21%), P <0.05. DAF density in the well‐differentiated Ishikawa cell line was two‐fold higher than in metastatic cell line AN3CA.
CONCLUSIONS: Our findings are consistent with a hypothesis that endometrial adenocarcinoma of early stage that is exposed to complement attack may up‐regulate DAF to protect malignant cells from complement lysis.